$1.79 Billion is the total value of Cormorant Asset Management, LP's 64 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ZNTL | New | ZENTALIS PHARMACEUTICALS INC | $30,889,950 | – | 1,095,000 | +100.0% | 1.73% | – |
| BBIO | New | BRIDGEBIO PHARMA INCput | $13,945,760 | – | 810,800 | +100.0% | 0.78% | – |
| ISEE | New | IVERIC BIO INCcall | $11,802,000 | – | 300,000 | +100.0% | 0.66% | – |
| PRAX | New | PRAXIS PRECISION MEDICINES I | $10,925,000 | – | 9,500,000 | +100.0% | 0.61% | – |
| IMVT | New | IMMUNOVANT INC | $10,433,500 | – | 550,000 | +100.0% | 0.58% | – |
| New | DISC MEDICINE INC | $9,990,000 | – | 225,000 | +100.0% | 0.56% | – | |
| RYTM | New | RHYTHM PHARMACEUTICALS INC | $9,894,000 | – | 600,000 | +100.0% | 0.55% | – |
| ARQT | New | ARCUTIS BIOTHERAPEUTICS INC | $7,624,000 | – | 800,000 | +100.0% | 0.43% | – |
| AKRO | New | AKERO THERAPEUTICS INC | $5,369,350 | – | 115,000 | +100.0% | 0.30% | – |
| APLS | New | APELLIS PHARMACEUTICALS INCcall | $3,552,900 | – | 39,000 | +100.0% | 0.20% | – |
| New | LEAP THERAPEUTICS INC | $3,358,634 | – | 1,073,046 | +100.0% | 0.19% | – | |
| OCUL | New | OCULAR THERAPEUTIX INC | $3,328,200 | – | 645,000 | +100.0% | 0.19% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
| 4 | 2024-03-11 |
| 13F-HR | 2024-02-14 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.